Global Insulin Delivery Devices Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Syringe, Pen, Jet Injector, Pumps, Others), By Application (Type I Diabetes, Type II Diabetes, Gestational Diabetes), By End User (Hospitals & Clinics, Ambulatory Care, Home Care), And By Geography - Forecasts From 2022 To 2027

  • Published : Dec 2022
  • Report Code : KSI061612023
  • Pages : 145

The global insulin delivery devices market is projected to witness a compound annual growth rate of 6.11% to grow to US$18.085 billion by 2027, from US$11.938 billion in 2020.

The growing prevalence of diabetes resulting in fatalities across the world coupled with increasing incidents of childhood diabetes dependent on insulin for care is anticipated to propel the market growth in the forecast period. According to the World Health Organization (WHO), diabetes was the direct cause of 1.5 million deaths and 48% of deaths resulting from diabetes occurred before the age of 70 years. Also, as per the WHO, raised blood glucose caused around 20% of cardiovascular diseases around the world in 2019. Also, according to the December 2021 article by the National Library of Medicine, the standardized incidence of type 1 diabetes in children increased from 17.1 per 100,000 PY in 1999 to 24.7 per 100,000 in 2019 which is also projected to increase to 34.8 per 100,000 PY in 2030. Growing type-1 diabetes is projected to fuel the demand for insulin, thereby increasing the market shares of the insulin delivery devices sector. Also, technological developments coupled with affordable product availability along with lack of access to insulin are together anticipated to push the market growth for insulin delivery devices at a significant scale during the forecast period.

Growth factors:

Growing diabetic population

According to the November 2021 release by the International Diabetes Federation, around 537 million people are living with diabetes worldwide, which is an increase of 16% from the 2019 numbers. Also, the source further stated that populated countries like China and India have the greatest number of diabetic people with 141 million and 74 million adults in the country. Further, as per the source, around 53.1% of the diabetic Indian population in India is undiagnosed with an additional 40 million people living with impaired glucose tolerance (IGT), which poses a high risk for developing type 2 diabetes thereby increasing the demand for insulin resulting in the market growth of insulin delivery devices as well.

Also, as per 2021 WHO Global Diabetes Compact Report, the source mentioned the lack of insulin availability to 50% of the people with type 2 diabetes, and the lack of human insulin in 39% of the health facilities in low- and middle-income countries. Aspects such as these are projected to offer market players increased penetration by offering insulin devices in the needed countries.

Technological advancement

As per the July 2021 news release by Rice University, the bioengineer team is using 3D printing in combination with smart biomaterials for creating an insulin-producing implant for Type 1 diabetes. The 3-year project is supported by a grant from JDRF, which is a global funder for research related to diabetes. Additionally, as per the source, 1.6 million Americans live with Type 1 diabetes, and more than 100 cases are diagnosed daily in the region. The development of technologies for battling type-1 diabetes and promoting insulin use is projected to offer the market players profitable market opportunities in the forecasted period.

Key development:

  • In January 2022, the Omnipod 5 was approved for use in Americans aged six years and older. Moreover, the FDA cleared the bolus insulin dosing on the t:slim X2 insulin pump from Tandem Diabetes Care, Inc. using the t: connect mobile app. The t: slim X2 insulin pump allows users to effortlessly configure and cancel bolus insulin requests using their smartphone with the new mobile application.

COVID-19 Impact on the Insulin Delivery Devices Market

The COVID-19 pandemic had a negative impact on the global insulin delivery devices market in 2020. The outbreak caused uncertainty in the outlook for the number of patients starting treatment as well as societal effects such as the unemployment rate, which affected healthcare insurance coverage. Furthermore, the pandemic had an impact on the worldwide supply chain system, which led to disturbances or delays in shipments of certain materials or components used in insulin delivery devices. Market players faced substantial issues in global transportation routes and other parts of the global supply chain network, such as the pricing and availability of raw materials and components as a result of constraints and cost inflation. Due to these limitations, major firms' revenue declined in 2020. Novo Nordisk A/S, for instance, saw a 5.27% decrease in total insulin sales in 2020.

Global Insulin Delivery Devices Market Scope:


Report Metric Details
 Market Size Value in 2020  US$11.938 billion
 Market Size Value in 2027  US$18.085 billion
 Growth Rate  CAGR of 6.11% from 2020 to 2027
 Base Year  2020
 Forecast Period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments Covered  Type, Application, End Users, And Geography
 Regions Covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies Covered Novo Nordisk A/S, Beckton, Dickinson and Company, Medtronic, Sanofi, Eli Lilly and Company, Ypsomed AG, Biocon Limited, Insulet Corporation, Tandem Diabetes Care, Inc., F. Hoffman-La Roche Ltd
 Customization Scope  Free report customization with purchase


Market Segmentation:

  • By Type
    • Syringes
    • Insulin Pumps
    • Inhalers
    • Others
  • By Application
    • Type I Diabetes
    • Type II Diabetes
    • Gestational Diabetes
  • By End-Users
    • Hospitals and Clinics
    • Ambulatory Care Centers
    • Home Care Settings
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germnay
      • France
      • UK
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • China
      • India
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Japan
      • Others

Frequently Asked Questions (FAQs)

The global insulin delivery devices market is expected to reach a market size of US$18.085 billion in 2027.
Insulin Delivery Devices Market was valued at US$11.938 billion in 2020.
The insulin delivery devices market is expected to grow at a CAGR of 6.11% over the forecast period.
The growing prevalence of diabetes is boosting the demand for insulin delivery devices globally which is boosting the market growth.
The insulin delivery devices market has been segmented by devices type, application, end-user, and geography.


1.1. Market Overview

1.2. COVID-19 Scenario

1.3. Market Definition

1.4. Market Segmentation



2.1. Research Design

2.2. Assumptions



3.1. Research Highlights



4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis



5.1. Introduction

5.2. Syringes

5.3. Insulin Pumps

5.4. Inhalers

5.5. Others



6.1. Introduction

6.2. Type I Diabetes

6.3. Type II Diabetes

6.4. Gestational Diabetes



7.1. Introduction

7.2. Hospitals and Clinics

7.3. Ambulatory Care Centers

7.4. Home Care Settings



8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. Germnay

8.4.2. France

8.4.3. UK

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. India

8.6.3. South Korea

8.6.4. Taiwan

8.6.5. Thailand

8.6.6. Indonesia

8.6.7. Japan

8.6.8. Others



9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix



10.1. Novo Nordisk A/S

10.2. Beckton, Dickinson and Company

10.3. Medtronic

10.4. Sanofi

10.5. Eli Lilly and Company

10.6. Ypsomed AG

10.7. Biocon Limited

10.8. Insulet Corporation

10.9. Tandem Diabetes Care, Inc.

10.10. F. Hoffman-La Roche Ltd.

Novo Nordisk A/S

Beckton, Dickinson and Company



Eli Lilly and Company

Ypsomed AG

Biocon Limited

Insulet Corporation

Tandem Diabetes Care, Inc.

F. Hoffman-La Roche Ltd